```
=> d his

     (FILE 'HOME' ENTERED AT 15:55:08 ON 10 JUN 2003)

     FILE 'MEDLINE' ENTERED AT 15:55:37 ON 10 JUN 2003
L1         13063 S SICKLE CELL
L2         39195 S ANTIVIRAL OR ACYCLOVIR OR VLACYLOVIR
L3           318 S VALACYCLOVIR
L4             0 S L3 AND L1
L5             9 S L2 AND L1

     FILE 'REGISTRY' ENTERED AT 16:00:41 ON 10 JUN 2003
L6            27 S ACYCLOVIR
L7             1 S ACYCLOVIR/CN
L8             1 S VALACYCLOVIR/CN

     FILE 'MEDLINE' ENTERED AT 16:02:35 ON 10 JUN 2003
L9          5053 S 59277-89-3
L10        13070 S SICKLE# CELL
L11            2 S L10 AND L9
L12            0 S 124832-26-4

     FILE 'REGISTRY' ENTERED AT 16:05:31 ON 10 JUN 2003
L13            1 S 124832-27-5

     FILE 'BIOSIS' ENTERED AT 16:06:15 ON 10 JUN 2003
L14          406 S VALACYCLOVIR OR VALACICLOVIR
L15         5711 S ACYCLOVIR OR ZOVIRAX OR ACICLOVIR
L16         5853 S L15 OR L14
L17        10631 S SICKLE# CELL
L18            1 S L17 AND L16

     FILE 'WPIDS' ENTERED AT 16:07:50 ON 10 JUN 2003
L19        11309 S ANTIVIRAL OR ACYCLOVIR OR VALACYCLOVIR
L20           30 S L19 AND L17

     FILE 'USPATFULL' ENTERED AT 16:11:02 ON 10 JUN 2003
L21         3755 S ACYCLOVIR OR ACICLOVIR
L22          280 S VALACYCLOVIR OR VALACICLOVIR
L23          536 S 59277-89-3/RN
L24           66 S 124832-26-4/RN
L25           14 S 124832-27-5/RN
L26         3899 S L21 OR L22 OR L23 OR L24 OR L25
L27         3067 S SICKLE# CELL
L28          198 S L26 AND L27
L29            1 S L26 (P) L27

     FILE 'MEDLINE' ENTERED AT 16:37:21 ON 10 JUN 2003
L30         6862 S HYDROXYUREA
L31        13070 S SICKLE# CELL
L32          324 S L30 AND L31
L33           12 S PREVENT SICKLING
L34        36259 S ANTIVIRAL
L35            2 S L34 AND L32
L36            0 S PD=1990
L37            0 S 1990/PD
L38            0 S 1990/DATE
L39       387715 S 1990/PY
L40          174 S L39 AND L30
L41            6 S L31 AND L40

=> log hold
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
```

| | ENTRY | SESSION |
|---|---|---|
| FULL ESTIMATED COST | 18.31 | 131.57 |

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:58:57 ON 10 JUN 2003

```
=> d his

     (FILE 'HOME' ENTERED AT 08:46:40 ON 11 JUN 2003)

     FILE 'REGISTRY' ENTERED AT 08:47:10 ON 11 JUN 2003
L1             1 S 5-AZACYTIDINE/CN

     FILE 'CA' ENTERED AT 08:47:57 ON 11 JUN 2003
L2          5088 S HYDROXYUREA
L3         37559 S ANTIVIRAL
L4           169 S L2 AND L3
L5          1401 S HYDROXYUREA/TI
L6            54 S L5 AND L3
                 S 320-67-2/REG#

     FILE 'REGISTRY' ENTERED AT 08:54:27 ON 11 JUN 2003
L7             1 S 320-67-2/RN

     FILE 'CA' ENTERED AT 08:54:27 ON 11 JUN 2003
L8          1266 S L7
L9          3408 S SICKLE# CELL
L10           14 S L8 AND L9

=> log hold
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                22.58      69.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                -2.48      -4.96

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 09:01:10 ON 11 JUN 2003
```

4

L6 ANSWER 51 OF 54 CA COPYRIGHT 2003 ACS
AN 121:292089 CA
TI **Hydroxyurea** as an inhibitor of human immunodeficiency virus-type 1 replication
AU Lori, Franco; Malykh, Andrei; Cara, Andrea; Sun, Daisy; Weinstein, John N.; Lisziewicz, Julianna; Gallo, Robert C.
CS Laboratory of Tumor Cell Biology, National Institutes of Health, Bethesda, MD, USA
SO Science (Washington, D. C.) (1994), 266(5186), 801-5
CODEN: SCIEAS; ISSN: 0036-8075
PB American Association for the Advancement of Science
DT Journal
LA English
AB Hydroxyurea, a drug widely used in therapy of several human diseases, inhibits deoxynucleotide synthesis- and, consequently, DNA synthesis-by blocking the cellular enzyme ribonucleotide reductase. Hydroxyurea inhibits human immunodeficiency virus-type 1 (HIV-1) DNA synthesis in activated peripheral blood lymphocytes by decreasing the amt. of intracellular deoxynucleotides, thus suggesting that this drug has an **antiviral** effect. Hydroxyurea has now been shown to block HIV-1 replication in acutely infected primary human lymphocytes (quiescent and activated) and macrophages, as well as in blood cells infected in vivo obtained from individuals with acquired immunodeficiency syndrome (AIDS). The **antiviral** effect was achieved at nontoxic doses of hydroxyurea, lower than those currently used in human therapy. Combination of hydroxyurea with the nucleoside analog didanosine (2',3'-dideoxyinosine, or ddI) generated a synergistic inhibitory effect without increasing toxicity. In some instances, inhibition of HIV-1 by hydroxyurea was irreversible, even several weeks after suspension of drug treatment. The indirect inhibition of HIV-1 by hydroxyurea is not expected to generate high rates of escape mutants. Hydroxyurea therefore appears to be a possible candidate for AIDS therapy.

=>